Citations

Clear

7 citation(s) found for "Anderson, Therese".

Pharmacogenomic augmented machine learning in electronic health record alerts: A health system‐wide usability survey of clinicians
Grant, Caroline W. , Marrero‐Polanco, Jean , Joyce, Jeremiah B. , Barry, Barbara , Stillwell, Ashley , Kruger, Kellie, Anderson, Therese , Talley, Heather Laine, Hedges, Mary S. , Valery, Jose R. , Sharp, Richard R. , Athreya, Arjun P. , Talley, Heather, Hedges, Mary S , Valery, Jose , White, Richard D , Sharp, Richard R , Croarkin, Paul E , Dyrbye, Liselotte N , V Bobo, William , Athreya, Arjun P , Joyce, Jeremiah , Barry, Barbara , Anderson, Therese F , Kruger, Kellie, Talley, Heather, White, Richard D. , Croarkin, Paul E. , Dyrbye, Liselotte N. , Bobo, William V.

Mayo Clinic

Clinical and Translational Science | October 15, 2024 | Volume: 17 | Issue: 10 | Pages: No page available

10.1111/cts.70044 | PMID 39402925 Get It

Abstract Pharmacogenomic (PGx) biomarkers integrated using machine learning can be embedded within the electronic health record (EHR) to provide clinicians with individualized predictions of drug treatment outcomes. Currently, however, drug alerts in the EHR are largely generic (not patient‐specific) and contribute to increased clinician stress and burnout. Improving the usability of PGx alerts is an urgent need. Therefore, this work aimed to identify principles for optimal PGx alert design through a health‐system‐wide, mixed‐methods study. Clinicians representing multiple practices and care settings ( N = 1062) in urban, rural, and underserved regions were invited to complete an electronic survey comparing the usability of three drug alerts for citalopram, as a case study. Alert 1 contained a generic warning of pharmacogenomic effects on citalopram metabolism. Alerts 2 and 3 provided patient‐specific predictions of citalopram efficacy with varying depth of information. Primary outcomes included the System's Usability Scale score (0–100 points) of each alert, the perceived impact of each alert on stress and decision‐making, and clinicians' suggestions for alert improvement. Secondary outcomes included the assessment of alert preference by clinician age, practice type, and geographic setting. Qualitative information was captured to provide context to quantitative information. The final cohort comprised 305 geographically and clinically diverse clinicians. A simplified, individualized alert (Alert 2) was perceived as beneficial for decision‐making and stress compared with a more detailed version (Alert 3) and the generic alert (Alert 1) regardless of age, practice type, or geographic setting. Findings emphasize the need for clinician‐guided design of PGx alerts in the era of digital medicine.
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
Bevers, Therese B. , Niell, Bethany L. , Bonaccio, Ermelinda, Camp, Melissa , Chikarmane, Sona A. , Eghtedari, Mohammad , Flanagan, Meghan R. , Hawley, Jeffrey , Helvie, Mark A. , Hodgkiss, Linda, Hoyt, Tamarya L., Ivanovich, Jennifer , Kulkarni, Swati , Lancaster, Rachael, Mauer, Caitlin , Pearlman, Mark D. , Philpotts, Liane E. , Plichta, Jennifer K. , Shakeri, Shadi Aminololama, Smith, Mary Lou , Streibert, Clarie L., Strigel, Roberta M. , Tumyan, Lusine , Winkler, Nicole , Wolverton, Dulcy , Bergman, Mary Anne, Stehman, Katie, Plichta, Jennifer K , Baker, Jennifer L. , Bennett, Debbie Lee , Conant, Emily F. , Jochelson, Maxine S. , Maxwell, Jessica, Patel, Bhavika , Plecha, Donna , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 900-909

10.6004/jnccn.2023.0046 | PMID 37673117 Get It

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.
Iatrogenic Arteriovenous Fistula Following Routine Venipuncture in an Adult Without Coagulopathy: An Uncommon Consequence of a Common Procedure
Anderson, Therese , Reese, Robyn L., McCann, Matthew R. , Alexander, Lauren F. , Salinas, Manisha , Anderson, Therese F , Reese, Robyn Lee, McCann, Matthew, Alexander, Lauren F

Mayo Clinic

Clinical Medicine Insights: Case Reports | May 29, 2023 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/11795476231177793 | PMID 37275675 Get It

Background: According to Tonnessen BH (2011), 1 iatrogenic arteriovenous (AV) fistulas in adults most commonly occur due to endovascular access and procedures. Rarely, AV fistulas have been reported in low birth weight neonates following repeating venipuncture. This complication is extremely uncommon in adults, but has been reported after routine venipuncture for blood transfusion. Case presentation: We report the case of an elderly female patient who presented to the office for evaluation of left upper extremity swelling, ecchymosis, and dilated vessels after routine venipuncture at an outpatient laboratory. She was subsequently found to have an acquired AV fistula from her left cephalic vein to a small branch artery. Conclusion: This case demonstrates the rare but relevant risk in routine venipuncture and may underscore the benefit of using ultrasound guidance in high-risk populations, such as patients with coagulopathies, or thin, fragile veins, like the elderly or neonates.
126. Outpatient Antimicrobial Stewardship Utilizing a Decentralized Model
McMullan, Stephen, Anderson, Therese , Boeff, Deborah, Bonner, William F., Epps, Kevin , LaCouture, Jacqueline, Leak, Michelle A. , Leybeg, Angelica, Riffe, Izabela, Schnusenberg, Lynda, Mendez, Julio, Anderson, Therese F , Powers, Harry, Bonner, William, Harris, Dana M.

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S176-S176

10.1093/ofid/ofab466.328 Get It

Abstract Background The majority of human antimicrobial utilization occurs in the outpatient setting. Despite being mainly viral in etiology, upper respiratory tract infections (URIs) were the most common indication for outpatient antimicrobial prescriptions at our institution. Methods Through our electronic health record (EHR), we were able to determine our rate of antibiotic prescriptions for inappropriate URI diagnosis at our primary care practice sites. We selected staff volunteers from each our primary care practice sites to serve as stewardship champions. They were given training in stewardship best practices, and an URI stewardship toolkit which included viral URI prescription pad, EHR order panel, and patient education signage. They were tasked with providing education and feedback to their practice sites. We meet with them on a monthly basis to disseminate prescribing data and education. They also provided feedback from practice sites to the stewardship committee. Results Our decentralized model was put in place in November 2020. In the 6 months prior to the intervention, the average prescribing rate was 29.1%. In the 6 months after the intervention, the average prescribing rate decreased by 15% to 24.8%. During the intervention phase, there was an increase in number of non-COVID URIs diagnosed at our primary care sites. Temporal Trend in Inappropriate Antibiotics Prescribing Rates for Viral URIs Pre- and Post- Intervention Inappropriate antibiotic prescribing rate for viral upper respiratory tract infections from May 2020 until May 2021. Intervention started in December 2021 (arrow). Pre-intervention average was 29.1%. Post-intervention age was 24.8% which is a 15% decline in prescribing rate. Viral Upper Respiratory Infections Visits The total number of visits for presumed viral upper respiratory infections to primary care sites from May 2020 until May 2021. The majority of COVID-19 precautions in the area expired at the end of March 2021. Conclusion We have been able to lower our inappropriate prescriptions for URIs utilizing a decentralized model of stewardship champions. This result was especially notable as the intervention phase corresponded with the end of COVID-19 precautions and an increase in non-COVID URIs diagnosed. The advantage of this approach includes an advocate embedded at each practice site who is familiar with the opportunities and challenges of the site, and a two-way flow of information from practice sites to the stewardship committee. This model provided additional benefit during the COVID-19 pandemic as the ability of centralized staff to travel to off campus clinic sites was curtailed. Disclosures All Authors: No reported disclosures
A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
Palomares, Melanie R. , Hageman, Lindsey , Chen, Yanjun , Landier, Wendy , Smith, Kandice, Umphrey, Heidi , Reich, Caroline A., Zamora, Kathryn , Armenian, Saro H. , Bevers, Therese B. , Henderson, Tara O. , Korde, Larissa A. , Melin, Susan A., Merajver, Sofía D. , Overholser, Linda , Pruthi, Sandhya , Wong, F. Lennie , Landier, Wendy , Smith, Kandice , Zamora, Kathryn W , Armenian, Saro H , Hudson, Melissa M , Garber, J. E. , Bhatia, Smita , Blaes, Anne , Hodgson, David , Hudson, Melissa M. , Garber, Judy E.

Mayo Clinic

Clinical Cancer Research | December 3, 2020 | Volume: 27 | Issue: 4 | Pages: 967-974

10.1158/1078-0432.ccr-20-3609 | PMID 33272980 Get It

Abstract Purpose: Low-dose tamoxifen reduces breast cancer risk, but remains untested in chest-irradiated cancer survivors—a population with breast cancer risk comparable with BRCA mutation carriers. We hypothesized that low-dose tamoxifen would be safe and efficacious in reducing radiation-related breast cancer risk. Patients and Methods: We conducted an investigator-initiated, randomized, phase IIb, double-blinded, placebo-controlled trial (FDA IND107367) between 2010 and 2016 at 15 U.S. sites. Eligibility included ≥12 Gy of chest radiation by age 40 years and age at enrollment ≥25 years. Patients were randomized 1:1 to low-dose tamoxifen (5 mg/day) or identical placebo tablets for 2 years. The primary endpoint was mammographic dense area at baseline, 1 and 2 years. IGF-1 plays a role in breast carcinogenesis; circulating IGF-1 and IGF-BP3 levels at baseline, 1 and 2 years served as secondary endpoints. Results: Seventy-two participants (low-dose tamoxifen: n = 34, placebo: n = 38) enrolled at a median age of 43.8 years (35–49) were evaluable. They had received chest radiation at a median dose of 30.3 Gy. Compared with the placebo arm, the low-dose tamoxifen arm participants had significantly lower mammographic dense area (P = 0.02) and IGF1 levels (P < 0.0001), and higher IGFBP-3 levels (P = 0.02). There was no difference in toxicity biomarkers (serum bone-specific alkaline phosphatase, lipids, and antithrombin III; urine N-telopeptide cross-links) between the treatment arms. We did not identify any grade 3–4 adverse events related to low-dose tamoxifen. Conclusions: In this randomized trial in chest-irradiated cancer survivors, we find that low-dose tamoxifen is effective in reducing established biomarkers of breast cancer risk and could serve as a risk-reduction strategy.
Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial
Palomares, Melanie R. , Hageman, Lindsey , Chen, Yanjun , Smith, Kandice, Umphrey, Heidi , Reich, Caroline A., Bevers, Therese B. , Henderson, Tara O. , Korde, Larissa A. , Melin, Susan A., Pruthi, Sandhya , Wong, Lennie, Bhatia, Smita , Landier, Wendy , Zamora, Kathryn , Armenian, Saro H. , Blaes, Anne , Hodgson, David , Hudson, Melissa M. , Merajver, Sofía D. , Overholser, Linda , Garber, Judy E.

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 2843-2843

10.1182/blood-2019-126661 Get It

Background: Lymphoma patients exposed to chest RT during adolescence/young adulthood are at increased risk for BC; the cumulative incidence exceeds 20% by age 45 and the BC risk is comparable to that in women with BRCA1 mutations. These findings present an urgent yet unmet need to reduce the risk of BC in RT-exposed lymphoma survivors. The risk of BC is 50% lower in chest RT-exposed survivors who also receive ovarian radiation, suggesting a critical role of endogenous estrogens in RT-related breast carcinogenesis, making tamoxifen (a selective estrogen receptor modulator) an attractive risk-reducing option. Tamoxifen administered at 20 mg/d is effective in BC prevention in other high risk populations, but severe adverse events (SAE: venous thromboembolism, endometrial cancer) have limited its broad use. Previous biomarker trials in the general population have shown that LDTam (5mg/d) is not inferior to tamoxifen at 20 mg/d in reducing BC risk, and is associated with a safer AE profile. Mammographic breast density (MBD) is an established biomarker of BC risk; high MBD is associated with a 4-fold higher risk of BC. We hypothesized that LDTam would be effective in reducing BC risk (using MBD as a primary endpoint) in chest RT-exposed lymphoma survivors. We used an investigator-initiated, multi-institutional, randomized phase IIb, double blind, placebo controlled trial (FDA IND 107367) to test this hypothesis. Methods: Female patients from 13 sites were ≥25y at enrollment, with a history of exposure to chest RT at ≥12 Gy by age 40 for their primary cancer, and were off therapy for ≥6 mo. Subjects with a prior history of BC/DCIS, B/L mastectomy, or baseline MBD <25% in both breasts were excluded. Tamoxifen 5mg or identical placebo tablets were provided by Sharp Clinical Services (Allentown, PA) under good manufacturing practice. Subjects were randomized 1:1 in a double-blinded fashion by a Web-based system to receive LDTam or placebo daily for 2y. MBD (in both breasts) was measured centrally on digital scans independently by 3 radiologists at baseline, 1y and 2y. Using an intention-to-treat analysis, the efficacy of LDTam in reducing MBD was compared between the LDTam and placebo arms by applying a linear mixed effects model for bivariate normally distributed data with random intercept and time*treatment arm effects. Correlations between the left and right breasts and within radiologists were accounted for in the model. Treating clinicians and all research staff were blinded to the treatment arm. Results: A total of 72 patients (LDTam: n=34; placebo: n=38) participated in the trial; primary diagnosis: Hodgkin lymphoma (86%); non-Hodgkin lymphoma (10%); other (3%); median age at diagnosis of primary cancer: 21.5y (IQR, 16-28), and at trial enrollment: 43.8y (35-49); median time from diagnosis of primary cancer to study: 17.0y (12-26). Median chest RT dose: 30.3 Gy (21-37.3); 11% had received pelvic radiation; 39% were post-menopausal at study. Participant characteristics were comparable between the two treatment arms, as was the mean baseline MBD (LDTam: 52.6% vs. placebo: 50.4%, p=0.6). The time*treatment arm effect was statistically significant (LDTam vs. placebo: estimate = -1.7, SE = 0.5, p = 0.001), indicating a significantly lower mean fitted MBD for LDTam (43.9%) vs. placebo (47.3%) at 2y (Figure). This represented a 16.5% relative reduction in MBD on the LDTam arm, corresponding to an estimated 33% lower risk of BC (assuming that reductions in MBD have the same benefit in lymphoma survivors as they do in the general population). There were no grade 3 or 4 AEs related to LDTam. Grade 2 AEs did not differ between treatment arms (LDTam: 44.1% vs. placebo: 36.8%, p=0.6). There was no difference in the prevalence of moderate-to-severe patient-reported outcomes between the treatment arms (Table). Conclusion: Low-dose tamoxifen was associated with a significantly steeper decline in MBD in chest RT-exposed lymphoma survivors, when compared with placebo, and was safe and well-tolerated. This is the first trial demonstrating efficacy of a pharmacologic intervention in reducing a biomarker strongly associated with breast cancer risk in lymphoma survivors with a past history of chest radiation. Disclosures Palomares: Covance: Other: Medical monitoring. Henderson:Seattle Genetics: Research Funding. OffLabel Disclosure: The drug is a low-dose tamoxifen, a selective estrogen receptor modulator. Tamoxifen in standard doses is used to reduce the risk of breast cancer in high risk populations. Tamoxifen in standard or low doses have not been tested before for chest-irradiated cancer survivors to reduce the risk of radiation-related breast cancer.
Personalized Assessment and Management of Women at Risk for Breast Cancer in North America
Pruthi, Sandhya , Heisey, Ruth, Bevers, Therese B.

Mayo Clinic

Women's Health | March 17, 2015 | Volume: 11 | Issue: 2 | Pages: 213-224

10.2217/whe.14.79 | PMID 25776295 Get It

Many women at increased risk for breast cancer would benefit from referral for genetic testing, enhanced screening, preventive therapy or risk-reducing surgery. We present a visual model and a step-wise approach to assist with a personalized risk stratification and management of these women. We present current recommendations with respect to lifestyle behaviors and mammographic screening, and we review the current evidence regarding enhanced screening and risk-reducing therapies. We discuss the usefulness of three risk-assessment tools in determining whether a woman qualifies for genetic testing, enhanced screening or preventive therapy and present four cases to demonstrate the usefulness of this approach in the clinical setting.